Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.

Autor:	Patrikidou, Anna1, Domont, Julien1, Chabaud, Sylvie2, Ray-Coquard, Isabelle2, Coindre, Jean-Michel3, Bui-Nguyen, Binh3, Adenis, Antoine4, Rios, Maria5, Bertucci, François6, Duffaud, Florence7, Chevreau, Christine8, Cupissol, Didier9, Pérol, David2, Emile, Jean-François10, Blay, Jean-Yves11, Cesne, Axel Le1 Axel.LECESNE@gustaveroussy.fr
Zdroj:	European Journal of Cancer. Jan2016, Vol. 52, p173-180. 8p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect